CE Course series: 3 CE credits
Set the record straight on hormone therapy and close the most overlooked treatment gap in midlife women’s health: GSM.
Course available for $525
What makes us different
Untangle decades of hormone therapy (HT) confusion with the current evidence and The Menopause Society’s 2022 Position Statement.
Close the GSM treatment gap: a chronic, progressive condition left untreated in the vast majority of women who have it.
Learn to identify optimal HT candidates using validated breast cancer and cardiovascular risk-assessment tools.
Walk away with evidence-based, culturally-informed language for starting HT and GSM conversations with patients.
Treatment of Menopause covers the two most consequential — and most misunderstood — areas of menopause care: hormone therapy (HT) and genitourinary syndrome of menopause (GSM). More than two decades after the Women’s Health Initiative study upended HT prescribing, misconceptions still shape clinical decisions, even though later data clarified the study’s major limitations. Meanwhile, GSM goes untreated in most women who have it, despite being chronic and unlikely to improve on its own. This course equips you to close both gaps with confidence.
For hormone therapy, you’ll get the current evidence base — including The Menopause Society’s 2022 Position Statement — and how to apply breast cancer and cardiovascular risk-assessment tools to identify optimal candidates. For GSM, you’ll get a full clinical framework: recognizing the hypoestrogenic changes behind it, validated screening tools, and hormonal and non-hormonal treatment options you can implement into practice immediately.
After participating in this activity, learners will be able to:
Overview
The WHI study in context, the current risk-benefit profile, and how dose, duration, route, and timing shape recommendations.
The hypoestrogenic changes behind GSM, its symptom domains, and validated assessment tools.
Breast cancer and cardiovascular risk-assessment tools to guide prescribing decisions.
Mechanisms, delivery routes, and clinical indications for each approach.
A comprehensive GSM work-up, appropriate labs, and hormonal and non-hormonal treatment options.
Starting evidence-based, culturally-informed conversations about HT and GSM.
Meet the team
Chief Medical Officer
Board Certified OB/GYN; Certified Menopause Provider and Board Certified in Lifestyle Medicine
Chief Medical Advisor for Let’s Talk Menopause
Medical Affairs
Certified Menopause Provider & Owner, Coastal Well Woman Menopause Clinic
20+ Years in Medical Affairs with Evofem, Suneva, and Allergan
Medical Writer
Former Director of Health Communications and Education at HerMD
10+ Years in Healthcare with Academic Research Experience at Dana-Farber Cancer Institute and Mt Sinai
In support of improving patient care, this activity has been planned and implemented by EncorVita™ Health and Pinnacle Conference, LLC. Pinnacle Conference, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Clinicians who prescribe or want to prescribe hormone therapy, and any provider looking to better recognize and treat GSM.
No. Foundations of Menopause is not required before taking this course. If you are newer to menopause care, it provides helpful background on the physiology, symptoms, diagnosis, and foundational concepts that inform the prescribing considerations covered here.
If you already have a strong foundation in menopause care and want to focus specifically on hormone therapy and prescribing considerations, you can jump directly into this course.
3 CE credits.
This is an enduring, self-paced online activity. You will have up to 12 months from the date of purchase to complete the course.
Yes, the course covers the evidence base for hormone therapy alongside non-hormonal GSM treatment options.
Yes. A knowledge assessment quiz with a minimum passing score of 80% is required to earn CE credit.
You will have unlimited opportunities to retake the assessment until you achieve a passing score.
Treatment of Menopause – EncorVita™ Health
Activity Date: August 24, 2026 – August 24, 2029
Activity Type: Enduring
CE: 3 total credits
This activity offers 3 CE credit(s) for:
*All other attendees will receive an AMA PRA Category 1 Credit™ participation certificate
This enduring educational activity consists of self-paced online modules designed to provide healthcare professionals with evidence-based education on the treatment of menopause, including hormone therapy and the diagnosis and management of genitourinary syndrome of menopause (GSM). Learners will progress through a structured curriculum that combines didactic instruction, interactive knowledge assessments, and clinical case-based learning to strengthen competence in individualized menopause management. Content is delivered through recorded educational modules, detailed PDF written material & tables, interactive learning activities, embedded quizzes, and clinical case scenarios. The self-paced format enables learners to complete the curriculum at their convenience while reinforcing knowledge through module-based assessments and clinical application exercises. To claim credit, participants must complete all required educational modules, complete the associated assessments, and submit the post-activity evaluation. Throughout the activity, learners will strengthen their ability to apply current evidence, individualize treatment decisions, and deliver patient-centered menopause care that improves symptom management, quality of life, and long-term health outcomes.
Menopause affects millions of women each year, yet many healthcare professionals report limited confidence in evaluating candidates for hormone therapy and managing common menopause-related conditions such as genitourinary syndrome of menopause (GSM). Although substantial evidence has emerged over the past two decades, persistent misconceptions regarding the risks and benefits of hormone therapy—particularly following the 2002 Women’s Health Initiative (WHI) publication—continue to influence clinical decision-making. Updated guidance from professional societies and evolving regulatory recommendations have clarified many of these issues, creating an ongoing need for education that reflects current evidence. Observable practice gaps include inappropriate avoidance of hormone therapy because of outdated risk perceptions, inconsistent cardiovascular and breast cancer risk assessment, limited familiarity with contemporary hormone formulations and routes of administration, inadequate screening for GSM, and underutilization of effective hormonal and nonhormonal treatment options. Because GSM symptoms are frequently underreported by patients and not routinely assessed by clinicians, many women experience persistent symptoms that negatively affect quality of life and sexual health.
This activity is suitable for Physicians, Nurses, Pharmacists, Physician Assistants, and other licensed healthcare professionals.
It is particularly relevant for physicians, nurse practitioners, physician assistants, registered nurses, pharmacists, and other licensed clinicians practicing in primary care, family medicine, internal medicine, obstetrics and gynecology, endocrinology, women’s health, and related specialties who provide care for women during the menopause transition.
It is the policy of Pinnacle Conference, LLC, to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. Pinnacle Conference, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Robin Noble, MD, MHCDS, MSCP, has disclosed several financial relationships: Chief Medical Officer, Equity, and Consulting at EncorVita Health; Medical Advisor, Equity, and Consulting at Play Health; Chief Medical Advisor, Equity, and Consulting at Mia Health; Equity and Consultant at Indagare; Chief Medical Advisor at Let’s Talk Menopause; Advisory Board and Equity at Bioceptive; Advisory Board and Equity at GYNtle; Advisory Board and Equity at Immugen; Advisory at DrKumo; Board Member and Shareholder Physician at Intermed, PA.
Laura Abrignani, NP, has disclosed several financial relationships: Speaker at Bayer Healthcare; Sr. Director, Medical Affairs at EncorVita Health.
Michelle Nezolosky, MPH, has disclosed several financial relationships: Independent Contractor at EncorVita Health; Independent Contractor at Eterna, Inc.; Employee at HerMD.
Isabelle Raymond, PhD, has disclosed several financial relationships: Employee at Nutraceutical Wellness Inc; Advisor and Investor at EncorVita Health.
Corinne Erickson, MD, has disclosed several financial relationships: Speaker at Hydrinity; Speaker at Cartessa; Consultant/Advisor at L’Oreal; Advisor at EncorVita Health.
Chad Schiffman, MHA, has disclosed a financial relationship: Reviewer of course content on behalf of EncorVita Health (via Healthcare Compliance Pros).
Robin Noble, MD, MHCDS, MSCP, has disclosed several financial relationships: Chief Medical Officer, Equity, and Consulting at EncorVita Health; Medical Advisor, Equity, and Consulting at Play Health; Chief Medical Advisor, Equity, and Consulting at Mia Health; Equity and Consultant at Indagare; Chief Medical Advisor at Let’s Talk Menopause; Advisory Board and Equity at Bioceptive; Advisory Board and Equity at GYNtle; Advisory Board and Equity at Immugen; Advisory at DrKumo; Board Member and Shareholder Physician at Intermed, PA.
Michelle Nezolosky, MPH, has disclosed several financial relationships: Independent Contractor at EncorVita Health; Independent Contractor at Eterna, Inc.; Employee at HerMD.
Laura Abrignani, NP, has disclosed several financial relationships: Speaker at Bayer Healthcare; Sr. Director, Medical Affairs at EncorVita Health.
Pamela Mehta, MD, has nothing to disclose.
Shafqat Abbas, PharmD, has nothing to disclose.
All relevant financial relationships have been evaluated and mitigated.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. Pinnacle Conference, LLC, the faculty, planners, and EncorVita™ Health do not endorse the use of any product outside of the FDA-labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, this activity has been planned and implemented by EncorVita™ Health and Pinnacle Conference, LLC. Pinnacle Conference, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Pinnacle Conference, LLC, designates this Enduring activity for a maximum of 3 AMA PRA Category 1 credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 credits™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 credit™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.
This activity is designated for 3 contact hours.
To receive CPE credit through CPE Monitor, please ensure you have provided your NABP ePID number and DOB appropriately. If you are unsure or would like to confirm, please contact ce@learnatpinnacle.com within 60 days of completing the activity.
Pinnacle Conference, LLC has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 3 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Pinnacle Conference, LLC (BOC AP#: JA4008385) is approved by the Board of Certification, Inc. to provide continuing education to Athletic Trainers (ATs). This program is eligible for a maximum of (3) Category A hours/CEUs. ATs should claim only those hours actually spent in the educational program.
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (1 IPCE credits = 1 CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (1 hour/60 minutes = 1 CPEU). RDs and DTRs are to select activity type 102 in their Activity Logs. Performance Indicator selection is at the learner’s discretion.
As a Jointly Accredited Organization, Pinnacle Conference, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 3 General continuing education credits.
Pinnacle Conference, LLC is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP. Pinnacle Conference, LLC designates this activity for 3 hours continuing education credits. Concerns or complaints about a CE provider may be directed to the provider, or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.
This activity was planned by and for the healthcare team, and learners will receive 3 Interprofessional Continuing Education (IPCE) credits for learning and change.
Enroll now to see pricing and get started
The clinical resources menopause didn’t have – until now
CE Course
CE Course
CE Course
CE Course
No courses match that category yet.
